STERIS plc (STE) shareholders
Close on Nov 13, 2026Market cap $25.77BP/E 31.4Yield 0.93%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,105,204 | 9.20% | 13G (passive) amendment | Sep 30, 2024 |
| Vanguard Capital Management | 7,340,236 | 7.48% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 4,995,259 | 5.10% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 4,962,018 | 5.05% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,820,889 | 9.05% | $1.86B | −205,732 | 0.03% |
| Vanguard Capital Management LLC | 6,406,906 | 6.57% | $1.35B | +40,528 | 0.03% |
| State Street Corp | 5,072,818 | 5.20% | $1.07B | +80,950 | 0.03% |
| Vanguard Portfolio Management LLC | 5,001,950 | 5.13% | $1.05B | +51,910 | 0.05% |
| Morgan Stanley | 3,950,067 | 4.05% | $831.77M | −444,196 | 0.04% |
| Massachusetts Financial Services Co /Ma/ | 3,801,077 | 3.90% | $850.36M | −209,272 | 0.27% |
| Wellington Management Group Llp | 3,502,897 | 3.59% | $737.61M | +629,532 | 0.13% |
| Orbis Allan Gray Ltd | 2,677,710 | 2.75% | $563.85M | +84,798 | 1.94% |
| Geode Capital Management, LLC | 2,615,842 | 2.68% | $548.62M | +34,109 | 0.03% |
| Generation Investment Management Llp | 2,280,698 | 2.34% | $480.25M | −27,761 | 4.67% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | 2,200,220 | 2.26% | $463.30M | +5,275 | 0.26% |
| Select Equity Group, L.P. | 1,894,646 | 1.94% | $398.96M | −248,733 | 1.97% |
| Jupiter Topco LLC | 1,887,828 | 1.94% | $397.52M | New | 0.16% |
| Price T Rowe Associates Inc /Md/ | 1,834,238 | 1.88% | $386.24M | +71,103 | 0.04% |
| Invesco Ltd. | 1,806,187 | 1.85% | $380.33M | +97,885 | 0.03% |
| Boston Partners | 1,498,334 | 1.54% | $315.50M | +636,081 | 0.28% |
| Aqr Capital Management LLC | 1,377,297 | 1.41% | $285.84M | +315,897 | 0.10% |
| Goldman Sachs Group Inc | 1,363,145 | 1.40% | $287.04M | +981,568 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 1,217,864 | 1.25% | $256.45M | +698,353 | 0.11% |
| Dimensional Fund Advisors LP | 1,199,619 | 1.23% | $252.64M | +85,774 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 830 | 95M | 97.4% | 105 / 299 | 305 / 101 | 12M | 8M |
| Q1 2026 | 843 | 94M | 96.2% | 85 / 273 | 353 / 128 | 22M | 9M |
| Q4 2025 | 896 | 93M | 95.2% | 143 / 339 | 276 / 72 | 10M | 9M |
| Q3 2025 | 842 | 92M | 94.7% | 103 / 337 | 273 / 85 | 7M | 7M |
| Q2 2025 | 834 | 92M | 94.5% | 118 / 337 | 259 / 55 | 6M | 6M |
| Q1 2025 | 778 | 92M | 94.9% | 97 / 293 | 282 / 68 | 6M | 4M |
| Q4 2024 | 763 | 91M | 93.7% | 97 / 254 | 308 / 80 | 7M | 10M |
| Q3 2024 | 755 | 95M | 97.2% | 78 / 247 | 305 / 58 | 13M | 5M |
| Q2 2024 | 743 | 96M | 98.7% | 68 / 285 | 271 / 43 | 5M | 13M |
| Q1 2024 | 721 | 104M | 100.0% | 71 / 292 | 236 / 49 | 8M | 3M |
| Q4 2023 | 704 | 99M | 100.0% | 86 / 250 | 262 / 48 | 10M | 4M |
| Q3 2023 | 678 | 93M | 95.0% | 74 / 240 | 256 / 39 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
294 funds held STE in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of STE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,114,554 | 3.19% | $655.83M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,542,447 | 2.61% | $535.36M | 0.03% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 2,124,977 | 2.18% | $447.46M | 0.20% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,100,961 | 1.13% | $251.46M | 0.66% | Jul 31, 2026 |
| Vanguard Windsor Fund | 956,066 | 0.98% | $218.37M | 0.86% | Jul 31, 2026 |
| Vanguard Value Index Fund | 932,649 | 0.96% | $196.39M | 0.08% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 895,540 | 0.92% | $204.54M | 0.21% | Jul 31, 2026 |
| Touchstone Funds Group Trust-Touchstone Mid Cap Fund | 580,068 | 0.59% | $122.14M | 2.71% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 554,901 | 0.57% | $126.74M | 0.10% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 532,611 | 0.55% | $112.15M | 0.03% | Jun 30, 2026 |
| iShares U.S. Medical Devices ETF | 459,271 | 0.47% | $96.71M | 3.20% | Jun 30, 2026 |
| Equity Income Fund | 404,633 | 0.42% | $92.42M | 1.16% | Jul 31, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 375,677 | 0.39% | $79.11M | 0.23% | Jun 30, 2026 |
| Vanguard Mid-Cap Value Index Fund | 314,961 | 0.32% | $66.32M | 0.18% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 294,734 | 0.30% | $62.70M | 0.33% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel A. Carestio | President and CEO, Director | 63,647 | 0.07% | Jun 8, 2026 |
| Karen L. Burton | Sr. Vice Pres., CFO | 12,956 | 0.01% | Nov 12, 2026 |
| John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | 35,259 | 0.04% | Jun 16, 2026 |
| Renato Tamaro | V.P. & Corporate Treasurer | 6,194 | 0.01% | Jun 8, 2026 |
| Mary Clare Fraser | SVP & Chief HRO | 13,716 | 0.01% | Jun 8, 2026 |
| Kenneth E. Kohler | SVP & GM, AST | 11,332 | 0.01% | Jun 8, 2026 |
| Julia Madsen | Sr. VP and GM, Life Sciences | 12,257 | 0.01% | Jun 8, 2026 |
| Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | 6,240 | 0.01% | Jun 4, 2026 |
| Cary L. Majors | SVP and President, Healthcare | 17,472 | 0.02% | Jun 4, 2026 |
| Michael J. Tokich | Sr. Vice Pres., CFO | 47,483 | 0.05% | Jun 6, 2025 |
| Mohsen Sohi | Director | 24,305 | 0.02% | Nov 12, 2026 |
| Christopher S. Holland | Director | 582 | 0.00% | Aug 12, 2026 |
| Esther M. Alegria | Director | – | – | Aug 12, 2026 |
| Louis Shapiro | Director | – | – | Aug 12, 2026 |
| Nirav R. Shah | Director | 292 | 0.00% | Aug 12, 2026 |
| Paul Edward Martin | Director | – | – | Aug 12, 2026 |
| Cynthia L. Feldmann | Director | 12,466 | 0.01% | Aug 12, 2026 |
| Pierre Boulud | Director | – | – | Aug 12, 2026 |
| Richard C. Breeden | Director | 66,206 | 0.07% | Jun 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Karen L. Burton Sr. Vice Pres., CFO | Nov 11, 2026 | Sale | −5,880 | $255.62 | $1.50M | 12,956 |
| Karen L. Burton Sr. Vice Pres., CFO | Nov 11, 2026 | Option exercise | +5,880 | $147.05 | $864.65K | 18,836 |
| Mohsen Sohi Director | Nov 10, 2026 | Sale | −1,665 | $253.90 | $422.74K | 24,305 |
| Mohsen Sohi Director | Nov 10, 2026 | Sale | −3,228 | $252.87 | $816.26K | 25,970 |
| Mohsen Sohi Director | Nov 10, 2026 | Option exercise | +4,893 | $114.74 | $561.42K | 29,198 |
| Karen L. Burton Sr. Vice Pres., CFO | Oct 1, 2026 | Tax withholding | −228 | – | – | 12,956 |
| Mohsen Sohi Director | Aug 12, 2026 | Sale | −4,058 | $235.78 | $956.80K | 24,305 |
| Mohsen Sohi Director | Aug 12, 2026 | Option exercise | +4,058 | $86.23 | $349.92K | 28,363 |
| Mohsen Sohi Director | Jul 1, 2026 | Tax withholding | −1,837 | $212.30 | $390.00K | 24,305 |
| Mohsen Sohi Director | Jul 1, 2026 | Option exercise | +3,781 | $71.40 | $269.96K | 26,142 |
| John Adam Zangerle Sr. VP, Gen Counsel, and Sec. | Jun 15, 2026 | Sale(10b5-1 plan) | −1,419 | $209.28 | $296.97K | 35,259 |
| Daniel A. Carestio President and CEO, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,374 | $212.00 | $291.29K | 63,647 |
| Renato Tamaro V.P. & Corporate Treasurer | Jun 4, 2026 | Tax withholding | −65 | $212.24 | $13.80K | 6,194 |
| Kenneth E. Kohler SVP & GM, AST | Jun 4, 2026 | Tax withholding | −150 | $212.24 | $31.84K | 11,332 |
| Daniel A. Carestio President and CEO, Director | Jun 4, 2026 | Tax withholding | −1,889 | $212.24 | $400.92K | 68,075 |
| Daniel A. Carestio President and CEO, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −3,054 | $214.64 | $655.51K | 65,021 |
| Mary Clare Fraser SVP & Chief HRO | Jun 4, 2026 | Tax withholding | −600 | $212.24 | $127.34K | 13,716 |
| Julia Madsen Sr. VP and GM, Life Sciences | Jun 4, 2026 | Tax withholding | −195 | $212.24 | $41.39K | 12,257 |
| John Adam Zangerle Sr. VP, Gen Counsel, and Sec. | Jun 4, 2026 | Tax withholding | −401 | $212.24 | $85.11K | 36,678 |
| Karen L. Burton Sr. Vice Pres., CFO | Jun 4, 2026 | Tax withholding | −90 | $212.24 | $19.10K | 13,184 |
| Kenneth E. Kohler SVP & GM, AST | Jun 3, 2026 | Tax withholding | −184 | $210.19 | $38.67K | 11,482 |
| Daniel A. Carestio President and CEO, Director | Jun 3, 2026 | Tax withholding | −2,619 | $210.19 | $550.49K | 69,964 |
| Julia Madsen Sr. VP and GM, Life Sciences | Jun 3, 2026 | Tax withholding | −239 | $210.19 | $50.24K | 12,452 |
| Karen L. Burton Sr. Vice Pres., CFO | Jun 3, 2026 | Tax withholding | −190 | $210.19 | $39.94K | 13,274 |
| Renato Tamaro V.P. & Corporate Treasurer | Jun 3, 2026 | Tax withholding | −64 | $210.19 | $13.45K | 6,259 |
| Mary Clare Fraser SVP & Chief HRO | Jun 3, 2026 | Tax withholding | −311 | $210.19 | $65.37K | 14,316 |
| John Adam Zangerle Sr. VP, Gen Counsel, and Sec. | Jun 3, 2026 | Tax withholding | −365 | $210.19 | $76.72K | 37,079 |
| Renato Tamaro V.P. & Corporate Treasurer | Jun 2, 2026 | Award | +750 | – | – | 6,364 |
| Renato Tamaro V.P. & Corporate Treasurer | Jun 2, 2026 | Tax withholding | −41 | $209.76 | $8.60K | 6,323 |
| Richard C. Breeden Director | Jun 2, 2026 | Sale | −1,481 | $209.51 | $310.28K | 38,964 |
| Richard C. Breeden Director | Jun 2, 2026 | Option exercise | +3,781 | $71.40 | $269.96K | 40,445 |
| Kenneth E. Kohler SVP & GM, AST | Jun 2, 2026 | Award | +2,199 | – | – | 11,732 |
| Kenneth E. Kohler SVP & GM, AST | Jun 2, 2026 | Tax withholding | −66 | $209.76 | $13.84K | 11,666 |
| Julia Madsen Sr. VP and GM, Life Sciences | Jun 2, 2026 | Tax withholding | −127 | $209.76 | $26.64K | 12,691 |
| Julia Madsen Sr. VP and GM, Life Sciences | Jun 2, 2026 | Award | +2,316 | – | – | 12,818 |
| Mary Clare Fraser SVP & Chief HRO | Jun 2, 2026 | Award | +3,009 | – | – | 15,218 |
| Mary Clare Fraser SVP & Chief HRO | Jun 2, 2026 | Tax withholding | −591 | $209.76 | $123.97K | 14,627 |
| Lindsey McGowan VP, Chf. Comp. & Quality Offc. | Jun 2, 2026 | Award | +1,155 | – | – | 5,985 |
| Lindsey McGowan VP, Chf. Comp. & Quality Offc. | Jun 2, 2026 | Tax withholding | −329 | $209.76 | $69.01K | 5,656 |
| Cary L. Majors SVP and President, Healthcare | Jun 2, 2026 | Award | +4,746 | – | – | 17,405 |
| Cary L. Majors SVP and President, Healthcare | Jun 2, 2026 | Tax withholding | −67 | $209.76 | $14.05K | 17,338 |
| Daniel A. Carestio President and CEO, Director | Jun 2, 2026 | Award | +23,736 | – | – | 73,578 |
| Daniel A. Carestio President and CEO, Director | Jun 2, 2026 | Tax withholding | −995 | $209.76 | $208.71K | 72,583 |
| Karen L. Burton Sr. Vice Pres., CFO | Jun 2, 2026 | Option exercise | −66 | $209.76 | $13.84K | 13,464 |
| Karen L. Burton Sr. Vice Pres., CFO | Jun 2, 2026 | Award | +5,325 | – | – | 13,530 |
| John Adam Zangerle Sr. VP, Gen Counsel, and Sec. | Jun 2, 2026 | Tax withholding | −247 | $209.76 | $51.81K | 37,444 |
| John Adam Zangerle Sr. VP, Gen Counsel, and Sec. | Jun 2, 2026 | Award | +4,359 | – | – | 37,691 |
| Cary L. Majors SVP and President, Healthcare | Jun 1, 2026 | Tax withholding | −768 | – | – | 12,659 |
| Kenneth E. Kohler SVP & GM, AST | Jun 1, 2026 | Tax withholding | −109 | – | – | 9,533 |
| Lindsey McGowan VP, Chf. Comp. & Quality Offc. | Jun 1, 2026 | Tax withholding | −198 | – | – | 4,830 |
| Daniel A. Carestio President and CEO, Director | Jun 1, 2026 | Tax withholding | −1,254 | – | – | 49,842 |
| Renato Tamaro V.P. & Corporate Treasurer | Jun 1, 2026 | Tax withholding | −81 | – | – | 5,614 |
| Mary Clare Fraser SVP & Chief HRO | Jun 1, 2026 | Tax withholding | −673 | – | – | 12,209 |
| Karen L. Burton Sr. Vice Pres., CFO | Jun 1, 2026 | Tax withholding | −99 | – | – | 8,205 |
| Julia Madsen Sr. VP and GM, Life Sciences | Jun 1, 2026 | Tax withholding | −208 | – | – | 10,502 |
| John Adam Zangerle Sr. VP, Gen Counsel, and Sec. | Jun 1, 2026 | Tax withholding | −337 | – | – | 33,332 |
| Cynthia L. Feldmann Director | Mar 5, 2026 | Option exercise | +3,098 | $152.32 | $471.89K | 3,803 |
| Cynthia L. Feldmann Director | Mar 5, 2026 | Sale | −3,098 | $237.21 | $734.88K | 705 |
| Lindsey McGowan VP, Chf. Comp. & Quality Offc. | Jan 2, 2026 | Award | +798 | – | – | 5,028 |
| Julia Madsen Sr. VP and GM, Life Sciences | Nov 21, 2025 | Option exercise | +2,872 | $114.22 | $328.04K | 13,582 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Steris's stock actually held short. Settlement fails (shares not delivered on time) peaked at 142 shares on Oct 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mohsen Sohi Director | Nov 10, 2026 | 4,893 | $1.24M | Nov 10, 2026 | Employee Stock Option Exercise |
| Richard C. Breeden Director | Aug 18, 2026 | 4,110 | $953.11K | Aug 18, 2026 | Exercise & Hold |
| Mohsen Sohi Director | Aug 12, 2026 | 4,058 | $956.78K | Aug 12, 2026 | Employee Stock Option Exercise |
| John Adam Zangerle Officer | Jun 15, 2026 | 1,419 | $296.97K | Jun 15, 2026 | Restricted Stock Lapse |
| Daniel A. Carestio Officer, Director | Jun 5, 2026 | 1,374 | $291.29K | Jun 5, 2026 | Restricted Stock Lapse |
| Daniel A. Carestio Officer, Director | Jun 4, 2026 | 3,054 | $655.51K | Jun 4, 2026 | Restricted Stock Lapse |
| Richard C. Breeden Director | Jun 2, 2026 | 1,481 | $310.29K | Jun 2, 2026 | Employee Stock Option Exercise |
| Cynthia L. Feldmann Director | Mar 5, 2026 | 3,098 | $734.87K | Mar 5, 2026 | Employee Stock Option Exercise |
| Julia Madsen Officer | Nov 21, 2025 | 5,008 | $1.31M | Nov 21, 2025 | Employee Stock Option Exercise |
| Renato Tamaro Officer | Nov 18, 2025 | 5,036 | $1.30M | Nov 18, 2025 | Employee Stock Option Exercise |
| John Adam Zangerle Officer | Nov 12, 2025 | 15,000 | $3.98M | Nov 11, 2025 | Employee Stock Option Exercise |
| Daniel A. Carestio Officer, Director | Oct 6, 2025 | 159 | $38.45K | Oct 6, 2025 | Restricted Stock Lapse |
| Renato Tamaro Officer | Aug 20, 2025 | 3,204 | $798.56K | Aug 20, 2025 | Employee Stock Option Exercise |
| Jacqueline B. Kosecoff Director | Aug 12, 2025 | 3,781 | $914.08K | Aug 12, 2025 | Employee Stock Option Exercise |
| Cynthia L. Feldmann Director | Aug 11, 2025 | 3,495 | $844.25K | Aug 11, 2025 | Employee Stock Option Exercise |
See a number that looks wrong?